glp-1/gip/glucagon triple agonist GLP-1 / GIP / Glucagon Receptor (CAS 2381089-83-2) Schematic illustration of monoagonists, dual

Further reading Florio T, Schettini G (September 2001)

Furthermore, there has been an indication of tirzepatide reducing liver fat, and improving nephrotic outcomes as evidenced by the lower urine albumin: creatinine ratio and the slower decline of estimated glomerular filtration rate in people with T2DM [56]

| Target Concentration | BAC Water to Add | Dose per 10 units on syringe | |---------------------|-----------------|------------------------------| | 5mg/ml | 2.0ml | 0.5mg | | 10mg/ml | 1.0ml | 1.0mg | **Best for:** Patients on 1-2mg weekly doses during titration weeks 1-8

Back Marks, V (1960) 'Response to glucagon by subjects with hyperinsulinism from islet tumours', British Medical Journal , 1, 1539-41